- There are a dozen Phase 3 COVID-19 vaccine candidates with more than 50 in either Phase 1 or Phase 2 trials. But the fact that Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have vaccine candidates with efficacy greater than 90% could ultimately narrow the playing field.
“Efficacy matters, but I don’t think [Pfizer’s and Moderna’s efficacy rate of] greater than 90% shuts others down in the near term,” said Navin Jacob, a senior equity research analyst specializing in biotech and pharmaceuticals at UBS.
Get the full story from our sister site, Drug Discovery & Development.